Victor Golmer/iStock Editorial via Getty Images
- To meet growing demand for chronic disease drugs, Novo Nordisk’s (NVO) Pharmatech unit will add an additional production facility in Koge, Denmark.
- The factory, which will create 50 new jobs, will cost DKK1.5B (~$221M).
- The facility is expected to open in 2027. It will produce silica gel, which is used in the manufacture of the company’s insulin and GLP-1 therapies, such Ozempic and Wegovy, Reuters reported.
- In March 2023, Novo bought a 47,000-square-meter site in Koge for the purposes of expanding active pharmaceutical ingredient production.
